Free Trial
NYSE:CNMD

CONMED Q3 2025 Earnings Report

CONMED logo
$45.42 -1.10 (-2.35%)
Closing price 10/9/2025 03:59 PM Eastern
Extended Trading
$45.40 -0.02 (-0.04%)
As of 10/9/2025 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CONMED EPS Results

Actual EPS
N/A
Consensus EPS
$1.06
Beat/Miss
N/A
One Year Ago EPS
N/A

CONMED Revenue Results

Actual Revenue
N/A
Expected Revenue
$334.76 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

CONMED Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Wednesday, November 5, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

CONMED Earnings Headlines

CONMED Corporation (CNMD): A Bull Case Theory
CONMED Corporation (CNMD): A Bull Case Theory
Buy UBER immediately
BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on some of the biggest winners of 2025.tc pixel
See More CONMED Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CONMED? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CONMED and other key companies, straight to your email.

About CONMED

CONMED (NYSE:CNMD) (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy. The Orthopedics segment offers arthroscopic shavers, burrs and handpieces, as well as joint repair and reconstruction implants. In its Visualization & Energy segment, CONMED provides endoscopic imaging systems, electrosurgical and radiofrequency generators, insufflators, ablation devices and related disposables. These technologies are designed to improve procedural efficiency, safety and patient outcomes.

With a presence in over 70 countries, CONMED sells products through direct sales forces as well as distributor partnerships. The company’s international footprint spans North America, Europe, Latin America, Asia Pacific and select emerging markets. CONMED works closely with healthcare facilities and surgical centers to deliver training, technical support and service solutions tailored to local regulatory requirements and clinical practices.

Leadership at CONMED includes President and Chief Executive Officer Jeffrey M. Dunn, whose tenure has focused on strategic growth through product innovation and targeted acquisitions. Over its history, the company has expanded both organically and via the integration of complementary businesses to broaden its capabilities in key procedural areas. CONMED remains committed to advancing minimally invasive surgical technologies and supporting clinicians worldwide.

View CONMED Profile

More Earnings Resources from MarketBeat